Oppenheimer Reiterates Buy Rating on EPRX
Oppenheimer maintains its buy stance on EPRX, targeting a $17 price, a 165.21% upside from the current price.
Key Points
- Oppenheimer reiterated its buy rating on EPRX, setting a price target of $17 on June 26, 2026.
- Oppenheimer's $17 price target implies 165.21% upside from Eupraxia Pharmaceuticals Inc.'s ($EPRX) current $6.41 share price.
- EPRX shares traded at $6.41 on Friday, reflecting ongoing interest from analysts.
- Institutional activity in EPRX includes a 429.7% increase by Affinity Asset Advisors, LLC, now holding 1,589,005 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Oppenheimer has reaffirmed its buy rating for EPRX, maintaining a target price of $17. This reiteration, made by analyst Jay Olson on June 26, 2026, signals continued confidence in the company's prospects.
Oppenheimer vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in EPRX
Several institutional investors have recently adjusted their positions in EPRX. Beutel, Goodman & Co Ltd. slightly reduced its holdings by 42,908 shares, now holding a total of 3,666,465 shares valued at approximately $26.4 million. On the other hand, Affinity Asset Advisors, LLC significantly increased its stake by 1,289,005 shares, marking a 429.7% rise, and now holds 1,589,005 shares worth about $11.5 million. Scotia Capital Inc. also boosted its position by 55,995 shares, a 4.4% increase, bringing its total to 1,342,178 shares valued at $7.2 million. Ikarian Capital, LLC expanded its holdings by 604,741 shares, achieving a 99.1% increase, resulting in 1,214,741 shares valued at approximately $8.8 million.
Analysts Set New Price Targets
On June 26, 2026, Oppenheimer reiterated its buy rating on EPRX with a $17 price target. Other analysts also shared positive outlooks: Stifel initiated coverage with a buy rating and a $25 target on May 21, 2026. Earlier in the year, HC Wainwright & Co. maintained its buy rating with an $11 target on March 17, 2026, and Cantor Fitzgerald maintained a buy rating with a $19 target on January 15, 2026.
About EPRX
EPRX is a company that operates in the healthcare sector, focusing on the development and commercialization of pharmaceuticals. The company aims to address unmet medical needs by offering innovative treatments. With its headquarters located in the United States, EPRX continues to explore new opportunities in the pharmaceutical industry.
Bottom Line
Oppenheimer's reaffirmation of its buy rating on EPRX with a $17 target on June 26, 2026, highlights the firm's positive outlook on the company's potential. EPRX's stock remains a point of interest for analysts and institutional investors alike. As always, it's important for investors to consider that these ratings are based on past data and may not reflect current market conditions.
Get Eupraxia Pharmaceuticals Inc. alerts
New 13F filings, insider trades, and analyst moves on $EPRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.